Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHFINDER II: EEG-guided MMGA in Cardiac Surgery
NCT05279898Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Randomised, single-blind trial of propofol injection (veterinary), dexmedetomidine, ketamine, remifentanil and ropivacaine hydrochloride liposomal suspension injection in postoperative delirium (POD), neurocognitive disorder (NCD) and pain (2 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Increase in Plasma IL-6 Levels and Increase in Plasma Neurofilament Light Levels. Started Feb 2023; status: completed.
02
Drugs
propofol injection (veterinary)dexmedetomidineketamineremifentanilropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative delirium (POD)neurocognitive disorder (NCD)pain
Beyond the preview
Go deeper on NCT05279898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279898.